Skip to content

Massimiliano Donzelli

4 papers in the library · 421 citations · publishing 2012-2013

Papers

Sort Most recent Most cited

Pharmacokinetic and pharmacodynamic effects of methylphenidate and MDMA administered alone or in combination

The International Journal of Neuropsychopharmacology October 8, 2013 Cédric M. Hysek, Linda D. Simmler, Nathalie Schillinger et al. 125 citations

Methylphenidate and 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') are widely misused psychoactive drugs. Methylphenidate increases brain dopamine and norepinephrine levels by blocking the presynaptic reuptake transporters. MDMA releases serotonin, dopamine and norepinephrine through the same transporters. Pharmacodynamic interactions of methylphenidate and MDMA are likely. This study...

α1-Adrenergic Receptors Contribute to the Acute Effects of 3,4-Methylenedioxymethamphetamine in Humans

Journal of Clinical Psychopharmacology July 13, 2013 Cédric M. Hysek, Anja E. Fink, Linda D. Simmler et al. 57 citations

Preclinical studies implicate a role for α₁-noradrenergic receptors in the effects of psychostimulants, including 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). The present study evaluated the effects of the α₁-noradrenergic receptor antagonist doxazosin on the acute pharmacodynamic and pharmacokinetic response to MDMA in 16 healthy subjects. Doxazosin (8 mg/d) or placebo was administered...

Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study

PLoS One May 4, 2012 Cédric M. Hysek, Linda D. Simmler, V.g. Nicola et al. 158 citations

UNLABELLED: This study assessed the effects of the serotonin (5-HT) and norepinephrine (NE) transporter inhibitor duloxetine on the effects of 3,4-methylenedioxy-methamphetamine (MDMA, ecstasy) in vitro and in 16 healthy subjects. The clinical study used a double-blind, randomized, placebo-controlled, four-session, crossover design. In vitro, duloxetine blocked the release of both 5-HT and NE...

Carvedilol inhibits the cardiostimulant and thermogenic effects of MDMA in humans

British Journal of Pharmacology March 8, 2012 Cédric M. Hysek, Yasmin Schmid, Anna Rickli et al. 81 citations

BACKGROUND AND PURPOSE The use of ±3,4‐methylenedioxymethamphetamine (MDMA, ‘ecstasy’) is associated with cardiovascular complications and hyperthermia. EXPERIMENTAL APPROACH We assessed the effects of the α 1 ‐ and β‐adrenoceptor antagonist carvedilol on the cardiostimulant, thermogenic and subjective responses to MDMA in 16 healthy subjects. Carvedilol (50 mg) or placebo was administered 1 h...